Enlivex doses first patient in its phase 1/2 trial of peritoneal cancer combo treatment

• Israel-based Enlivex Therapeutics (NASDAQ:ENLV) on Wednesday said the first patient had been dosed in its phase 1/2 clinical trial evaluating its cell therapy Allocetra in combination with chemotherapy to treat cancer of the peritoneum.
• ENLV stock +7.5% at $4.90 in afternoon trading.
• The early-to-mid stage trial is expected to enroll about 12 patients across four cohorts and will evaluate the safety and potential preliminary efficacy of Allocetra in combination with chemotherapy in peritoneal cancer patients.
• This is the initiation of the company's first oncology trial, according to ENLV CEO Oren Hershkovitz.
• The trial is taking place at Israel's Sheba Medical Center hospital.